|
Gene: GUCY2C |
Gene summary for GUCY2C |
Gene summary. |
Gene information | Species | Human | Gene symbol | GUCY2C | Gene ID | 2984 |
Gene name | guanylate cyclase 2C | |
Gene Alias | DIAR6 | |
Cytomap | 12p12.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P25092 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2984 | GUCY2C | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.53e-10 | -4.55e-01 | 0.0155 |
2984 | GUCY2C | HTA11_347_2000001011 | Human | Colorectum | AD | 2.71e-02 | 4.43e-01 | -0.1954 |
2984 | GUCY2C | HTA11_3361_2000001011 | Human | Colorectum | AD | 6.89e-06 | -5.33e-01 | -0.1207 |
2984 | GUCY2C | HTA11_696_2000001011 | Human | Colorectum | AD | 2.29e-03 | -3.14e-01 | -0.1464 |
2984 | GUCY2C | HTA11_99999970781_79442 | Human | Colorectum | MSS | 4.25e-06 | -3.40e-01 | 0.294 |
2984 | GUCY2C | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.97e-03 | 5.58e-01 | 0.281 |
2984 | GUCY2C | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.63e-04 | -3.95e-01 | 0.3005 |
2984 | GUCY2C | F007 | Human | Colorectum | FAP | 2.47e-02 | -3.16e-01 | 0.1176 |
2984 | GUCY2C | A001-C-207 | Human | Colorectum | FAP | 2.70e-04 | -2.92e-01 | 0.1278 |
2984 | GUCY2C | A015-C-203 | Human | Colorectum | FAP | 1.13e-32 | -4.31e-01 | -0.1294 |
2984 | GUCY2C | A015-C-204 | Human | Colorectum | FAP | 1.04e-07 | -4.28e-01 | -0.0228 |
2984 | GUCY2C | A014-C-040 | Human | Colorectum | FAP | 1.58e-02 | -1.72e-02 | -0.1184 |
2984 | GUCY2C | A002-C-201 | Human | Colorectum | FAP | 1.29e-11 | -3.27e-01 | 0.0324 |
2984 | GUCY2C | A002-C-203 | Human | Colorectum | FAP | 2.43e-06 | -2.09e-01 | 0.2786 |
2984 | GUCY2C | A001-C-119 | Human | Colorectum | FAP | 9.64e-06 | -3.97e-01 | -0.1557 |
2984 | GUCY2C | A001-C-108 | Human | Colorectum | FAP | 3.28e-24 | -3.39e-01 | -0.0272 |
2984 | GUCY2C | A002-C-205 | Human | Colorectum | FAP | 4.93e-24 | -5.61e-01 | -0.1236 |
2984 | GUCY2C | A001-C-104 | Human | Colorectum | FAP | 4.42e-06 | -3.46e-01 | 0.0184 |
2984 | GUCY2C | A015-C-006 | Human | Colorectum | FAP | 3.14e-16 | -5.25e-01 | -0.0994 |
2984 | GUCY2C | A015-C-106 | Human | Colorectum | FAP | 5.00e-12 | -3.38e-01 | -0.0511 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0009150 | Colorectum | AD | purine ribonucleotide metabolic process | 142/3918 | 368/18723 | 4.29e-15 | 1.17e-12 | 142 |
GO:0006163 | Colorectum | AD | purine nucleotide metabolic process | 149/3918 | 396/18723 | 1.08e-14 | 2.80e-12 | 149 |
GO:0072521 | Colorectum | AD | purine-containing compound metabolic process | 153/3918 | 416/18723 | 4.34e-14 | 1.01e-11 | 153 |
GO:0009259 | Colorectum | AD | ribonucleotide metabolic process | 144/3918 | 385/18723 | 5.25e-14 | 1.13e-11 | 144 |
GO:0019693 | Colorectum | AD | ribose phosphate metabolic process | 145/3918 | 396/18723 | 3.01e-13 | 5.71e-11 | 145 |
GO:0009117 | Colorectum | AD | nucleotide metabolic process | 168/3918 | 489/18723 | 2.20e-12 | 3.36e-10 | 168 |
GO:0006753 | Colorectum | AD | nucleoside phosphate metabolic process | 169/3918 | 497/18723 | 4.99e-12 | 6.98e-10 | 169 |
GO:0009152 | Colorectum | AD | purine ribonucleotide biosynthetic process | 64/3918 | 169/18723 | 3.09e-07 | 1.22e-05 | 64 |
GO:0009636 | Colorectum | AD | response to toxic substance | 88/3918 | 262/18723 | 1.12e-06 | 3.72e-05 | 88 |
GO:0009260 | Colorectum | AD | ribonucleotide biosynthetic process | 66/3918 | 182/18723 | 1.25e-06 | 4.02e-05 | 66 |
GO:0046390 | Colorectum | AD | ribose phosphate biosynthetic process | 67/3918 | 190/18723 | 3.21e-06 | 9.05e-05 | 67 |
GO:0006164 | Colorectum | AD | purine nucleotide biosynthetic process | 66/3918 | 191/18723 | 8.22e-06 | 1.97e-04 | 66 |
GO:0072522 | Colorectum | AD | purine-containing compound biosynthetic process | 68/3918 | 200/18723 | 1.12e-05 | 2.55e-04 | 68 |
GO:1901293 | Colorectum | AD | nucleoside phosphate biosynthetic process | 80/3918 | 256/18723 | 6.31e-05 | 1.05e-03 | 80 |
GO:0009165 | Colorectum | AD | nucleotide biosynthetic process | 79/3918 | 254/18723 | 8.33e-05 | 1.30e-03 | 79 |
GO:00061632 | Colorectum | MSS | purine nucleotide metabolic process | 128/3467 | 396/18723 | 2.04e-11 | 3.02e-09 | 128 |
GO:00091502 | Colorectum | MSS | purine ribonucleotide metabolic process | 121/3467 | 368/18723 | 2.08e-11 | 3.02e-09 | 121 |
GO:00725212 | Colorectum | MSS | purine-containing compound metabolic process | 132/3467 | 416/18723 | 4.13e-11 | 4.86e-09 | 132 |
GO:00092592 | Colorectum | MSS | ribonucleotide metabolic process | 123/3467 | 385/18723 | 1.17e-10 | 1.20e-08 | 123 |
GO:00196932 | Colorectum | MSS | ribose phosphate metabolic process | 124/3467 | 396/18723 | 4.11e-10 | 3.49e-08 | 124 |
Page: 1 2 3 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
GUCA2A | GUCY2C | GUCA2A_GUCY2C | GUCA | CRC | AD |
GUCA2A | GUCY2C | GUCA2A_GUCY2C | GUCA | CRC | ADJ |
GUCA2B | GUCY2C | GUCA2B_GUCY2C | GUCA | CRC | ADJ |
GUCA2A | GUCY2C | GUCA2A_GUCY2C | GUCA | CRC | FAP |
GUCA2A | GUCY2C | GUCA2A_GUCY2C | GUCA | CRC | Healthy |
GUCA2A | GUCY2C | GUCA2A_GUCY2C | GUCA | CRC | MSS |
GUCA2A | GUCY2C | GUCA2A_GUCY2C | GUCA | CRC | SER |
GUCA2B | GUCY2C | GUCA2B_GUCY2C | GUCA | CRC | SER |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GUCY2C | SNV | Missense_Mutation | novel | c.2919N>C | p.Lys973Asn | p.K973N | P25092 | protein_coding | deleterious(0.02) | possibly_damaging(0.471) | TCGA-CN-4723-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
GUCY2C | SNV | Missense_Mutation | novel | c.1535G>T | p.Arg512Leu | p.R512L | P25092 | protein_coding | tolerated(0.27) | benign(0.06) | TCGA-CN-6010-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
GUCY2C | SNV | Missense_Mutation | rs192199843 | c.2056N>T | p.Arg686Trp | p.R686W | P25092 | protein_coding | tolerated(0.23) | benign(0.007) | TCGA-CN-6994-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
GUCY2C | SNV | Missense_Mutation | rs771651235 | c.3037N>A | p.Pro1013Thr | p.P1013T | P25092 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CR-7388-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
GUCY2C | SNV | Missense_Mutation | novel | c.1253C>T | p.Ser418Phe | p.S418F | P25092 | protein_coding | tolerated(0.08) | benign(0.044) | TCGA-CV-A45O-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
GUCY2C | SNV | Missense_Mutation | novel | c.2333N>A | p.Leu778Gln | p.L778Q | P25092 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CV-A461-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
GUCY2C | SNV | Missense_Mutation | novel | c.2004N>G | p.Ile668Met | p.I668M | P25092 | protein_coding | deleterious(0) | possibly_damaging(0.722) | TCGA-D6-A6ES-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
GUCY2C | SNV | Missense_Mutation | novel | c.1013N>C | p.Ile338Thr | p.I338T | P25092 | protein_coding | tolerated(0.52) | benign(0.001) | TCGA-F7-A622-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
GUCY2C | insertion | Frame_Shift_Ins | novel | c.2268_2269insGGAAACAAATCCTATATAGATAC | p.Asn757GlyfsTer16 | p.N757Gfs*16 | P25092 | protein_coding | TCGA-H7-8502-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | unknown | SD | ||
GUCY2C | SNV | Missense_Mutation | rs367698688 | c.1645G>C | p.Gly549Arg | p.G549R | P25092 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-J4-A67K-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 7 | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2984 | GUCY2C | DRUGGABLE GENOME, KINASE | agonist | 178101714 | LINACLOTIDE | |
2984 | GUCY2C | DRUGGABLE GENOME, KINASE | agonist | 178101551 | ||
2984 | GUCY2C | DRUGGABLE GENOME, KINASE | agonist | 374883898 | DOLCANATIDE | |
2984 | GUCY2C | DRUGGABLE GENOME, KINASE | SP-333 | DOLCANATIDE | ||
2984 | GUCY2C | DRUGGABLE GENOME, KINASE | agonist | CHEMBL3301675 | LINACLOTIDE | |
2984 | GUCY2C | DRUGGABLE GENOME, KINASE | antibody | 252827376 | ||
2984 | GUCY2C | DRUGGABLE GENOME, KINASE | PLECANATIDE | PLECANATIDE | ||
2984 | GUCY2C | DRUGGABLE GENOME, KINASE | MLN0264 | INDUSATUMAB VEDOTIN | ||
2984 | GUCY2C | DRUGGABLE GENOME, KINASE | MD-1100 | LINACLOTIDE | ||
2984 | GUCY2C | DRUGGABLE GENOME, KINASE | ISIS-GCCRrx |
Page: 1 2 |